HomePHIO • NASDAQ
add
Phio Pharmaceuticals Corp
Previous close
$1.25
Day range
$1.17 - $1.29
Year range
$0.81 - $4.19
Market cap
13.59M USD
Avg Volume
7.43M
P/E ratio
-
Dividend yield
-
Primary exchange
NASDAQ
Market news
Financials
Income Statement
Revenue
Net income
| (USD) | Dec 2025info | Y/Y change |
|---|---|---|
Revenue | — | — |
Operating expense | 1.06M | 53.41% |
Net income | -2.37M | -45.82% |
Net profit margin | — | — |
Earnings per share | -0.15 | — |
EBITDA | -2.53M | -51.31% |
Effective tax rate | — | — |
Balance Sheet
Total assets
Total liabilities
| (USD) | Dec 2025info | Y/Y change |
|---|---|---|
Cash and short-term investments | 21.03M | 290.77% |
Total assets | 21.49M | 274.47% |
Total liabilities | 1.34M | 32.02% |
Total equity | 20.15M | — |
Shares outstanding | 11.62M | — |
Price to book | 0.72 | — |
Return on assets | -38.40% | — |
Return on capital | -42.25% | — |
Cash Flow
Net change in cash
| (USD) | Dec 2025info | Y/Y change |
|---|---|---|
Net income | -2.37M | -45.82% |
Cash from operations | -2.08M | -51.64% |
Cash from investing | 0.00 | -100.00% |
Cash from financing | 12.40M | 815.50% |
Net change in cash | 10.33M | 129,175.00% |
Free cash flow | -1.29M | -64.92% |
About
Phio Pharmaceuticals Corporation is a US clinical stage biotechnology company developing its INTASYL siRNA in immuno-oncology. Formerly known as RXi Pharmaceuticals, the company's name was changed to Phio Pharmaceuticals in 2018. Wikipedia
Founded
2011
Website
Employees
6
